MANNKIND CORP: management transactions · United States · SEC (Form 4)

About MANNKIND CORP

MannKind Corp. is a U.S.-based biopharmaceutical company listed on the NASDAQ (United States) and focused on therapies for serious unmet medical needs, with an emphasis on endocrine disease and orphan lung diseases. Incorporated in Delaware in 1991, the company is headquartered in Danbury, Connecticut, which also serves as an important center for development and manufacturing activities tied to its proprietary inhaled-drug platform. MannKind’s business model blends marketed products, collaboration revenue, and a development pipeline built around differentiated pulmonary delivery technologies. ([sec.gov](https://www.sec.gov/Archives/edgar/data/899460/000119312526073516/mnkd-20251231.htm?utm_source=openai)) The company’s core commercial franchise sits in endocrinology. MannKind markets Afrezza, an ultra-rapid-acting inhaled insulin approved by the FDA in 2014 for adults with diabetes, and V-Go, a wearable continuous insulin delivery device that MannKind acquired in 2022 from Zealand Pharma. MannKind is responsible for U.S. commercialization of both products, giving it direct exposure to the U.S. diabetes market, which is large and competitive but supported by durable long-term demand. Afrezza remains the company’s flagship product, while V-Go broadens MannKind’s reach into device-based insulin delivery. ([sec.gov](https://www.sec.gov/Archives/edgar/data/899460/000095017025027735/mnkd-20241231.htm)) MannKind’s strategic differentiator is its Technosphere platform, paired with Dreamboat inhaler technology, which enables dry-powder formulations designed for rapid pulmonary delivery. The platform has already been validated commercially through Tyvaso DPI, an inhaled treprostinil product for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Tyvaso DPI is marketed by United Therapeutics, which pays MannKind royalties on net sales and also purchases supply from MannKind. This collaboration provides an important recurring revenue stream and underscores the value of MannKind’s drug-device capabilities beyond its own branded products. ([sec.gov](https://www.sec.gov/Archives/edgar/data/899460/000095017025027735/mnkd-20241231.htm)) On the R&D side, MannKind is pursuing orphan lung disease programs, including MNKD-101, a nebulized clofazimine formulation for chronic and recurrent pulmonary infections such as nontuberculous mycobacterial lung disease, and MNKD-201, a dry-powder formulation of nintedanib for idiopathic pulmonary fibrosis. In 2024, the company initiated a global Phase 3 registrational study for MNKD-101 with sites across the United States, Japan, South Korea, Taiwan, and Australia. However, in November 2025 MannKind announced it was discontinuing that Phase 3 trial after a futility review, highlighting the clinical execution risk that remains embedded in the pipeline. In August 2025, MannKind also amended its collaboration with United Therapeutics to add an additional product option, including a $5 million upfront payment and up to $35 million in potential milestones. ([sec.gov](https://www.sec.gov/Archives/edgar/data/899460/000095017025027735/mnkd-20241231.htm)) For international equity investors, MannKind represents a niche small-cap biotech with a diversified but still concentrated revenue base. The investment case hinges on Afrezza and V-Go commercial performance, continued royalty/supply monetization from Tyvaso DPI, and whether the company can convert its inhalation technology into additional clinically and commercially relevant products. ([sec.gov](https://www.sec.gov/Archives/edgar/data/899460/000095017025027735/mnkd-20241231.htm))